Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine.

Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. Abstract Text:

Takeshi Ichinohe,Shin-Ichi Tamura,Akira Kawaguchi,Ai Ninomiya,Masaki Imai,Shigeyuki Itamura,Takato Odagiri,Masato Tashiro,Hidehiro Takahashi,Hirofumi Sawa,William M Mitchell,David R Strayer,William A Carter,Joe Chiba,Takeshi Kurata,Tetsutaro Sata,Hideki Hasegawa,Takeshi Ichinohe,Shin-Ichi Tamura,Akira Kawaguchi,Ai Ninomiya,Masaki Imai,Shigeyuki Itamura,Takato Odagiri,Masato Tashiro,Hidehiro Takahashi,Hirofumi Sawa,William M Mitchell,David R Strayer,William A Carter,Joe Chiba,Takeshi Kurata,Tetsutaro Sata,Hideki Hasegawa,Takeshi Ichinohe,Shin-Ichi Tamura,Akira Kawaguchi,Ai Ninomiya,Masaki Imai,Shigeyuki Itamura,Takato Odagiri,Masato Tashiro,Hidehiro Takahashi,Hirofumi Sawa,William M Mitchell,David R Strayer,William A Carter,Joe Chiba,Takeshi Kurata,Tetsutaro Sata,Hideki Hasegawa,

BACKGROUND: Avian H5N1 influenza A virus is an emerging pathogen with the potential to cause substantial human morbidity and mortality. We evaluated the ability of currently licensed seasonal influenza vaccine to confer cross-protection against highly pathogenic H5N1 influenza virus in mice. METHODS: BALB/c mice were inoculated 3 times, either intranasally or subcutaneously, with the trivalent inactivated influenza vaccine licensed in Japan for the 2005-2006 season. The vaccine included A/NewCaledonia/20/99 (H1N1), A/NewYork/55/2004 (H3N2), and B/Shanghai/361/2002 viral strains and was administered together with poly(I):poly(C(12)U) (Ampligen) as an adjuvant. At 14 days after the final inoculation, the inoculated mice were challenged with either the A/HongKong/483/97, the A/Vietnam/1194/04, or the A/Indonesia/6/05 strain of H5N1 influenza virus. RESULTS: Compared with noninoculated mice, those inoculated intranasally manifested cross-reactivity of mucosal IgA and serum IgG with H5N1 virus, as well as both a reduced H5N1 virus titer in nasal-wash samples and increased survival, after challenge with H5N1 virus. Subcutaneous inoculation did not induce a cross-reactive IgA response and did not afford protection against H5N1 viral infection. CONCLUSIONS: Intranasal inoculation with annual influenza vaccine plus the Toll-like receptor-3 agonist, poly(I):poly(C(12)U), may overcome the problem of a limited supply of H5N1 virus vaccine by providing cross-protective mucosal immunity against H5N1 viruses with pandemic potential.

Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. Publishing Authors By Initials

T Ichinohe,S Tamura,A Kawaguchi,A Ninomiya,M Imai,S Itamura,T Odagiri,M Tashiro,H Takahashi,H Sawa,WM Mitchell,DR Strayer,WA Carter,J Chiba,T Kurata,T Sata,H Hasegawa,T Ichinohe,S Tamura,A Kawaguchi,A Ninomiya,M Imai,S Itamura,T Odagiri,M Tashiro,H Takahashi,H Sawa,WM Mitchell,DR Strayer,WA Carter,J Chiba,T Kurata,T Sata,H Hasegawa,T Ichinohe,S Tamura,A Kawaguchi,A Ninomiya,M Imai,S Itamura,T Odagiri,M Tashiro,H Takahashi,H Sawa,WM Mitchell,DR Strayer,WA Carter,J Chiba,T Kurata,T Sata,H Hasegawa,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: The Journal of infectious diseases

VOLUME: 196

Page Numbers: 1313-20

Journal Abbreviation: J. Infect. Dis.

ISSN: 0022-1899

DAY: 5

MONTH: 10

YEAR: 2007

Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 413675

Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine.

AFFILIATION: Department of Pathology, National Institute of Infectious Diseases, Musashimurayama-Shi, Tokyo, Japan.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Infect Dis

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine Related Publications

• An enhanced self-organizing incremental neural network for online unsupervised learning.
• Body mass index reference values (mean and SD) for Japanese children.
• Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human alpha-synuclein: Implication for alpha-synucleinopathies.
• Central administration of neuromedin U suppresses food intake in chicks.
• Chemokine blockade for lupus model mice.
• Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine.
• Distribution of inclusion bodies in tissues from 100 dogs infected with canine distemper virus.
• Effect of MMP/ADAM inhibitors on goblet cell hyperplasia in cultured human bronchial epithelial cells.
• Effect of prostaglandin E2 on recombinant human bone morphogenetic protein-2-stimulated osteoblastic differentiation in human periodontal ligament cells.
• Extraskeletal osteosarcoma of the jaw.
• Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen.
• Interferon-gamma inhibits collagen phagocytosis in human fibroblasts by inducing subcortical actin assembly and reducing ability of beta1 integrin to bind to collagen.
• Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge.
• Parkinson's Disease Treatment Guidelines 2002 issued by Societas Neurologica Japonica.
• Participation of endogenous IGF-I and TGF-beta 1 with enamel matrix derivative-stimulated cell growth in human periodontal ligament cells.
• Phylogenetic relationships of rodent pinworms (genus Syphacia) in Japan inferred from mitochondrial CO1 gene sequences.
• Possible involvement of organic anion and cation transporters in renal excretion of xanthine derivatives, 3-methylxanthine and enprofylline.
• Production of inhibin A and inhibin B in boars: changes in testicular and circulating levels of dimeric inhibins and characterization of inhibin forms during testis growth.
• Progress in SPECT/CT imaging of prostate cancer.
• Prolonged stress will induce Alzheimer's disease in elderly people by increased release of homocysteic acid.
• Recombinant human bone morphogenetic protein-2 stimulates osteoblast differentiation and suppresses matrix metalloproteinase-1 production in human bone cells isolated from mandibulae.
• Recombinant human bone morphogenetic protein-2 stimulates osteoblastic differentiation in cells isolated from human periodontal ligament.
• Role of neutrophils in acute inflammatory liver injury.
• Sensor fusion for taste sensor and odor sensor.
• Single nucleotide polymorphism genotyping of CYP2C19 using a new automated system.
• Sumoylation, a post-translational regulatory process in plants.
• [Detection of FDG-PET and FDG-PET/CT in head and neck squamous cell carcinoma]
• [Homocysteine metabolism]
• [Non-Q wave myocardial infarction (N-QMI)]
• [Subendocardial infarction]